News & Publications

Check out our news and publications

EVENTS

Posters

MNM 2018 - ER STRESS

04-05 October 2018, Munich (Germany)
Activation of the PERK pathway reduces the proteinopathy associated with neurodegenerative diseases : evidence from in vitro models of AD, PD and ALS.

Download

IAPRD 2018 - PD

19-22 August 2018, Lyon (France)
Acute dopaminergic neurotoxicity of alphasynuclein oligomers is mediated by microglial cells.

Download

IAPRD 2018 - PD (SNC1)

19-22 August 2018, Lyon (France)
Neuroprotective effects of SNC-1 (Ethnodyne Neuro®), a natural product used in ayurvedic traditional medicine, on in vitro models of Parkinson’s disease.

Download

SOCIETE DES NEUROSCIENCES - AD

7-8 June 2018, Strasbourg (France)
ER-stress regulation and effect of Guanabenz in primary cortical neurons injured with Aβ1-42 peptide, an in vitro model of Alzheimer’s disease.

Download

AAT-AD/PD 2018 - AD

15-18 March 2018, Torino (Italy)
A new treatment for Alzheimer’s disease : AZP2006 prevents and reverses amyloid and Tau damages via release of one growth factor and reduction of neuroinflammation.

Download

MNM 2017 - PD (SNC1)

28-29 September 2017, London (UK)
SNC-1 a natural food supplement, a promising candidate for the treatment of Parkinson’s Disease.

Download

MNM 2017 - BBB

28-29 September 2017, London (UK)
Effects of circulating and neuronal amyloid peptide oligomers on BBB integrity : consequences for the disease.

Download

AAIC 2017 - BBB

16-20 July 2017, London (UK)
Effects of circulating and neuronal amyloid peptide oligomers on the BBB integrity : consequences on the neurodegeneration process.

Download

AD/PD 2017 - PD

29 March - 02 April 2017, Vienna (Austria)
MPP+ induced dopaminergic neuron death through necroptosis and autophagy.

Download

AD/PD 2017 - ALS

29 March - 02 April 2017, Vienna (Austria)
Amyloid peptide and cytoplasmic TDP-43 accumulation in pathogenesis of ALS : an in vitro study.

Download

MNM 2016 - AD/BBB

29-30 September 2016, London (UK)
A novel triple cell co-culture model for mimicking the BBB into normal or pathological situations.

Download

AAIC 2016 - AD

22-28 July 2016, Toronto (Canada)
Mode of action study of NSP01-E, a potential treatment for Alzheimer’s disease, in protection against amyloid β peptide (Aβ) injury.

Download

MYOLOGY 2016 - ALS

14-18 March 2016, Lyon (France)
Pathological role of amyloid peptide in neuromuscular disease, glutamate and glucose involvement.

Download

JSFM 2015 - ALS

23-25 November 2015, Lyon (France)
Deleterious effects of amyloid beta peptide in the neuromuscular junction : consequences in ALS disease.

Download

PHYT’AROM 2015 - SNC-1

5-7 June 2015, Grasse (France)
Neuroprotective effect of SNC-1 a natural plant extract. Promising treatment for Alzheimer’s and Parkinson’s disease ?

Download

AD/PD 2015 - PD

18-22 March 2015, Nice (France)
α-synuclein : cause or consequence of cytopathological lesions observed in in vitro models of Parkinson’s disease.

Download

AD/PD 2015 - AD

18-22 March 2015, Nice (France)
Neurodegeneration induced by Aβ oligomeric fractions : role of NMDA receptors and mGluR5.

Download

ARUK CONF. 2015 - AD

10-11 March 2015, London (UK)
NSP01-E01 and NSP01-C01 : new preparations able to protect from beta-amyloid peptide (Aβ) injuries. Potential treatments for Alzheimer’s disease.

Download

SFN 2014 - PD

15-19 November 2014, Washington (USA)
Study of mitochondrial death pathways in different cellular models of Parkinson’s disease : effect of 17β-Estradiol.

Download

SFN 2014 - AD

15-19 November 2014, Washington (USA)
Beta-estradiol protects cortical neurons from beta-amyloid oligomers toxicity through mediations of the Ras/raf and PI3K pathways.

Download

ICNMD 2014 - ALS

5-10 July 2014, Nice (France)
Role of β-Amyloid (Aβ) Oligomeric fractions in ALS disease.

Download

Publications